22-HN-37-MSD (689-07): A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell

Grants and Contracts Details

StatusActive
Effective start/end date5/11/235/10/25

Funding

  • Merck Sharp & Dohme Corporation: $89,224.00